Flavio Vincenti
University of California San Francisco School of Medicine: Transplantation · University of California, San Francisco · University of California at San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Flavio Vincenti as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04066114 · Treg Modulation With CD28 and IL-6 Receptor AntagonistsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Living-Donor Kidney Transplant, Kidney Transplant Recipients · principal investigator
- N/ANCT03794817 · Immune Monitoring in Sensitized Patients at Risk of RejectionUniversity of California, San Francisco · completed · Kidney Failure · principal investigator
- Ph4NCT02939365 · Precision Medicine Offers Belatacept MonotherapyUniversity of California, San Francisco · withdrawn · Transplantation · principal investigator
- Ph1/Ph2NCT02711826 · Treg Therapy in Subclinical Inflammation in Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant · principal investigator
- Ph2NCT02108600 · Tocilizumab for Renal Graft InflammationFlavio Vincenti · completed · Late Complication From Kidney Transplant · principal investigator
- Ph1NCT02088931 · Treg Adoptive Therapy for Subclinical Inflammation in Kidney TransplantationUniversity of California, San Francisco · completed · Late Complication From Kidney Transplant · principal investigator
- N/ANCT01771705 · NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant PatientsUniversity of California, San Francisco · completed · Kidney Transplantation · principal investigator
- Ph1/Ph2NCT00777400 · Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg CellsUniversity of California, San Francisco · withdrawn · Autoimmune Diseases · principal investigator
- N/ANCT00695097 · The Effect of Rituximab on the Development of Anti-Donor AntibodiesUniversity of California, San Francisco · completed · Renal Transplant Rejection · principal investigator
- Ph2NCT00346151 · Belatacept to Prevent Organ Rejection in Kidney Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Renal Transplant · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)U01AI113362 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2014 to 2023 · $634,397 awarded in 2023Same name and institution; not confirmed by an ID
- THE EFFECT OF RITUXIMAB ON THE DEVELOPMENT OF ANTI DONOR ANTIBODIES AND RESOLM01RR000079 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2005 · $5,145 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.Transplantation · 1997930 citationsRCR 30.8
- A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Am J Transplant · 2010769 citationsRCR 21.0
- Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.N Engl J Med · 1998686 citationsRCR 16.4
- Costimulation blockade with belatacept in renal transplantation.N Engl J Med · 2005681 citationsRCR 15.5
- Belatacept and Long-Term Outcomes in Kidney Transplantation.N Engl J Med · 2016621 citationsRCR 23.1
- Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.Am J Transplant · 2007481 citationsRCR 13.8
- A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).Am J Transplant · 2010460 citationsRCR 13.1
- The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.Am J Transplant · 2010422 citationsRCR 13.5
- Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.Transplantation · 1998296 citationsRCR 10.1
- A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.Transplantation · 2002269 citationsRCR 7.6